Sarepta Therapeutics, Inc.
SRPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $1 |
| % Growth | -34.6% | -18% | 13.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1 | $1 |
| % Margin | 62.2% | 75% | 81.5% | 79.9% |
| R&D Expenses | $0 | $0 | $1 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Income | -$0 | $0 | -$0 | $0 |
| % Margin | -25.9% | 18.9% | -40.3% | 24.6% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | $0 | -$0 | $0 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -45.1% | 32.2% | -60.1% | 24.2% |
| EPS | -1.795 | 2.01 | -4.6 | 1.65 |
| % Growth | -189.3% | 143.7% | -378.8% | – |
| EPS Diluted | -1.795 | 1.89 | -4.6 | 1.5 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | $0 |
| % Margin | -42.1% | 27.8% | -49.5% | 28.4% |